COMMUNIQUÉS West-GlobeNewswire

Publication relative à des notifications de transparence
03/10/2025
INFORMATION RÉGLEMENTÉE Publication relative à des notifications de transparence Mont-Saint-Guibert (Belgique), le 3 octobre 2025 , 22:30h CET / 16:30h ET – Conformément à l'article 14 de la loi du 2 mai 2007 relative à [...]
Publication relating to transparency notifications
03/10/2025
REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), October 3, 2025 , 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the [...]
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
03/10/2025
NOVATO, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare [...]
Contemporary Care Introduces TMS Therapy to Naples, Florida
03/10/2025
FDA-approved non-invasive treatment for depression and OCD now available at Contemporary Care’s Naples clinic Image by Contemporary Care NAPLES, Fla., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Contemporary Care today announced [...]
MESA LABS DECLARES QUARTERLY DIVIDEND
03/10/2025
Lakewood, Colo., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0 [...]
Frontier Medicines Announces Publication in Structure Highlighting Novel E3 Ligase DCAF2 can be Harnessed for Targeted Protein Degradation
03/10/2025
- First report of high-resolution structures of DCAF2 - - Frontier™ Platform key to discovering covalent ligands to selectively target DCAF2 - BOSTON and SOUTH SAN FRANCISCO, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- [...]
Mesa Laboratories, Inc. to Announce Second Quarter Results on November 6, 2025
03/10/2025
LAKEWOOD, Colo., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the second quarter of fiscal year 2026 following market close on Thursday, [...]
Smith+Nephew announce latest scientific data supporting new ALLEVYN™ COMPLETE CARE 5-Layer Foam Dressing for pressure injury prevention
03/10/2025
Smith+Nephew (NYSE:SNN; LSE:SN), the global medical technology business, is pleased to announce exciting new data from Professor Amit Gefen and his research group published in the International Wound Journal , 1 [...]
Press release: Transparency Notification from Shareholder
03/10/2025
Transparency Notification from Shareholder Ghent, Belgium – 3 October 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the " Company " or " Sequana Medical "), a pioneer in the treatment of drug-resistant fluid [...]
Vivani Medical Withdraws Record Date for Cortigent Neuromodulation Subsidiary Spin-Off
03/10/2025
The Company expects to reestablish and announce a new record date as soon as possible ALAMEDA, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage [...]
Enara Bio to Reveal DARKFOX, a Novel Cancer-Specific Dark Antigen with Broad-Ranging Therapeutic Potential, in Oral Presentation at SITC 2025
03/10/2025
Oxford, United Kingdom – October 3, 2025. Enara Bio , a biopharmaceutical company pioneering the discovery of novel Dark Antigens® and the development of bispecific T cell engagers for solid tumors, will present two [...]
Anathapindika Health’s Detoxifying Supplements Are Headed to Retailers in the US
03/10/2025
The Company’s Name Comes From Its Root Cause: to Provide Effective, Natural Solutions to Those Battling Health Issues. Soon, American Consumers Will Have Access to Those Solutions. Fort Lauderdale, FL, Oct. 03, 2025 ( [...]
BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025
03/10/2025
SAN DIEGO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB) , a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics using its [...]
Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
03/10/2025
WALTHAM, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living [...]
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
03/10/2025
WATERTOWN, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated [...]
Anathapindika Is Bringing Holistic Health to the US Through a Trio of Unconventional Nutraceutical Formulas
03/10/2025
Anthapindika Health’s Flagship Product Bundle Addresses Overall Health and Well-Being Through Comprehensive Detoxing and Cleansing Fort Lauderdale, FL, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Anathapindika Health has been [...]
Evaxion to present new biomarker data for AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting
03/10/2025
New biomarker and immune data from the ongoing phase 2 trial with EVX-01 will be presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting The data will be the latest of many additions to EVX-01’s [...]
ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
03/10/2025
Company will share data demonstrating CD47 overexpression as key predictive biomarker for response with the Company’s lead candidate, evorpacept, in HER2+ gastric cancer SOUTH SAN FRANCISCO, Calif., Oct. 03, 2025 (GLOBE [...]
Candel Therapeutics to Present at the SITC 2025 Annual Meeting
03/10/2025
NEEDHAM, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies [...]

Pages